Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745687 | 0.69 | — | — | |
| SCHEMBL5608367 | 0.68 | MAPT (0.30) | — | |
| SCHEMBL5702908 | 0.67 | MEN1 (0.33) | ALDH1A1CYP3A4 | |
| SCHEMBL14882722 | 0.66 | — | — | |
| SCHEMBL8615581 | 0.66 | ALDH1A1 (0.33) | ALDH1A1HSD17B10 | |
| SCHEMBL2643477 | 0.64 | — | — | |
| SCHEMBL27354175 | 0.64 | CYP3A4 (0.36) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8745139 | 0.63 | MAOB (0.44) | ALDH1A1HSD17B10 | |
| SCHEMBL2701352 | 0.63 | MAOB (0.36) | — | |
| SCHEMBL1712171 | 0.61 | TSHR (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807436-B1 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | INTEZYNE TECHNOLOGIES INC (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2502941-A1 | Heterobifunctional poly (ethylene glycol) and uses thereof | Intezyne Technologies Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8268936-B2 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120196989-A1 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2348096-A2 | Synthesis of hybrid block copolymers and uses thereof | Intezyne Technologies Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110124840-A1 | Synthesis of Homopolymers and Block Copolymers | INTEZYNE TECHNOLOGIES, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20110021718-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | INTEZYNE TECHNOLOGIES (US) | 2011-01-27 | — | — | US | disclosed |
| US-7612153-B2 | conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7601796-B2 | polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2067801-A1 | Synthesis of Hybrid Block Copolymers | Intezyne Technologies Incorporated (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1833958-A4 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | INTEZYNE TECHNOLOGIES INC (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1848460-A2 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | Intezyne Technologies Incorporated (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1833958-A2 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | Intezyne Technologies Incorporated (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1807436-A2 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | Intezyne Technologies Incorporated (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006086325-A2 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060172914-A1 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006074202-A2 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060142506-A1 | Heterobifunctional poly(ethylene glycol) and uses thereof | INTEZYNE TECHNOLOGIES, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006047419-A2 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142506-A1 | Heterobifunctional poly(ethylene glycol) and uses thereof | GNE, ALG1, EPHX2 | ALDH1A1 1837/4885CYP1A2 2705/4885CYP3A4 2194/4885 |
| US-20110124840-A1 | Synthesis of Homopolymers and Block Copolymers | PARG, PCNA, PARN | ALDH1A1 4499/4885CYP1A2 1901/4885CYP3A4 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.